A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

Anne M. Traynor, Ju Whei Lee, Gerald K. Bayer, John M. Tate, Sachdev P. Thomas, Miroslaw Mazurczak, David L. Graham, Jill M. Kolesar, Joan H. Schiller

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. Methods: Triapine 105 mg/m2 IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine® related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). Conclusion: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.

Original languageEnglish (US)
Pages (from-to)91-97
Number of pages7
JournalInvestigational New Drugs
Volume28
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Survival
Genotype
Methemoglobinemia
Therapeutics
3-aminopyridine-2-carboxaldehyde thiosemicarbazone

Keywords

  • ATP binding cassette transporter
  • Combination chemotherapy
  • Non-small cell lung cancer
  • Ribonucleotide reductase
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer : Eastern Cooperative Oncology Group Study 1503. / Traynor, Anne M.; Lee, Ju Whei; Bayer, Gerald K.; Tate, John M.; Thomas, Sachdev P.; Mazurczak, Miroslaw; Graham, David L.; Kolesar, Jill M.; Schiller, Joan H.

In: Investigational New Drugs, Vol. 28, No. 1, 01.2010, p. 91-97.

Research output: Contribution to journalArticle

Traynor, Anne M. ; Lee, Ju Whei ; Bayer, Gerald K. ; Tate, John M. ; Thomas, Sachdev P. ; Mazurczak, Miroslaw ; Graham, David L. ; Kolesar, Jill M. ; Schiller, Joan H. / A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer : Eastern Cooperative Oncology Group Study 1503. In: Investigational New Drugs. 2010 ; Vol. 28, No. 1. pp. 91-97.
@article{4c6382b47ef848ea95654f5f7d7cf480,
title = "A phase II trial of Triapine{\circledR} (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503",
abstract = "Background: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. Methods: Triapine 105 mg/m2 IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20{\%}) experienced stable disease (90{\%} CI 5.7-44{\%}). Median overall survival: 5.4 months (95{\%} CI 4.2-11.6 months); median time to progression: 1.8 months (95{\%} CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine{\circledR} related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). Conclusion: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.",
keywords = "ATP binding cassette transporter, Combination chemotherapy, Non-small cell lung cancer, Ribonucleotide reductase, Single nucleotide polymorphism",
author = "Traynor, {Anne M.} and Lee, {Ju Whei} and Bayer, {Gerald K.} and Tate, {John M.} and Thomas, {Sachdev P.} and Miroslaw Mazurczak and Graham, {David L.} and Kolesar, {Jill M.} and Schiller, {Joan H.}",
year = "2010",
month = "1",
doi = "10.1007/s10637-009-9230-z",
language = "English (US)",
volume = "28",
pages = "91--97",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer

T2 - Eastern Cooperative Oncology Group Study 1503

AU - Traynor, Anne M.

AU - Lee, Ju Whei

AU - Bayer, Gerald K.

AU - Tate, John M.

AU - Thomas, Sachdev P.

AU - Mazurczak, Miroslaw

AU - Graham, David L.

AU - Kolesar, Jill M.

AU - Schiller, Joan H.

PY - 2010/1

Y1 - 2010/1

N2 - Background: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. Methods: Triapine 105 mg/m2 IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine® related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). Conclusion: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.

AB - Background: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. Methods: Triapine 105 mg/m2 IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15, of a 28 day cycle. Results: Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine® related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). Conclusion: This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.

KW - ATP binding cassette transporter

KW - Combination chemotherapy

KW - Non-small cell lung cancer

KW - Ribonucleotide reductase

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=74149093251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149093251&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9230-z

DO - 10.1007/s10637-009-9230-z

M3 - Article

C2 - 19238328

AN - SCOPUS:74149093251

VL - 28

SP - 91

EP - 97

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -